---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-002173"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:26:38.235231+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics appoints Martin Dewhurst to its Board of Directors

## Summary
- Board expanded from 5 to 6 members; Dewhurst appointed as independent Class III director effective Jan 7, 2026.
- Over 30 years life sciences experience; former McKinsey senior partner and co-leader of global life sciences practice.
- Received initial RSU grant with $100,000 fair value, vesting at one year or change of control.
- Will chair compensation committee; eligible for annual $70,000 RSU grant after first anniversary of direct listing.

## SEC filing metadata
- accession: 0001213900-26-002173
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026002173/0001213900-26-002173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026002173/ea0272109-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-002173
- JSON: https://secwatch.observer/filing/0001213900-26-002173.json
- Plain text: https://secwatch.observer/filing/0001213900-26-002173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.